| | Today's Big News Sep 12, 2022 This year's Fierce 15 is here. We’re celebrating 2022's best biotech startups, with a particular focus on diversity in management and geography. Bristol Myers Squibb’s deucravacitinib has won FDA approval for moderate-to-severe plaque psoriasis, and projects that the drug could potentially bring in more than $4 billion in revenue. Verily just got a $1 billion boost from parent company Alphabet that will go toward expansion efforts. Alongside the eye-popping funding round, Alphabet has also announced several leadership shakeups among its life sciences arm. - Gabrielle Masson | Lumanity’s research scientists and data luminaries can identify fit-for-purpose RWD and design studies to generate the strongest evidence to meet stakeholder needs. Learn more. 
|
| By Ben Adams Welcome to this year's Fierce Biotech's Fierce 15. Join us in celebrating 2022's best of the best biotech startups. This year, we focused more than ever before on diversity in management and geography across the biotech world, highlighting a broader range of teams, leaders and science. |
|
|
By Zoey Becker Back when Bristol Myers Squibb acquired Celgene in 2019 for $74 billion, it opted to keep the dermatology and immunology drug deucravacitinib, as opposed to the already-approved Otezla. And now, BMS doesn’t regret this move in the slightest. Deucravacitinib has won FDA approval for moderate-to-severe plaque psoriasis. By Heather Landi Verily is preparing to expand its precision health businesses and got a $1 billion boost from its parent company to fuel its next stage of growth. By Conor Hale The advent of blood tests that can detect multiple different cancers at early stages will not only reshape how the disease is diagnosed but will bring about a major shift in the delivery of care. By Max Bayer In a race to design the next era of checkpoint inhibitors, AstraZeneca PD-L1 and CTLA-4 bispecific show efficacy rivaling data against Keytruda in first line lung cancer patients. But the dose level eliciting strong durability also came with significant toxicity, spurring a dose reduction. By Angus Liu Bristol Myers Squibb's and Roche's immunotherapies have both failed to move the needle when used after surgery in early-stage kidney cancer. But the two companies’ setbacks aren’t necessarily a full relief for Merck’s rival drug Keytruda. By Max Bayer EZH2 inhibitors have shown their potential—already with one approved therapy and a few in the pipeline—and Pfizer is one of the latest biopharmas to add the tool to its clinical belt. And phase 1 data presented at the European Society of Medical Oncology congress 2022 point to a positive safety profile, with glimpses of benefit for some cancer patients, though not all. By Paige Minemyer When the CVS Caremark team geared up to take on health disparities, it quickly realized that any initiative would require a significant basis in data to succeed. By Andrea Park Artificial intelligence has increasingly become a go-to tool—rather than a novelty—for drugmakers looking to build the next generation of groundbreaking therapeutics. By Kevin Dunleavy In its ongoing investment push, Merck KGaA will pour €130 million ($132 million) into beefing up the ability of its manufacturing arm—MilliporeSigma—to employ single-use assemblies at its facility in Molsheim, France. By Frank Diamond A judicial ruling last week challenges the system that protects many patients from having to make copayments for preventive care. By Andrea Park Just a few months after beginning a review of “strategic alternatives” to its existing business plan—and proceeding to lay off around two-thirds of its full-time employees—Ra Medical has plotted a new route to potential financial success. By Gabrielle Masson Investors such as Pfizer have flooded Nimbus Therapeutics with $125 million in private financing, money that will go toward three clinical inflammatory and autoimmune disorder programs, including a phase 3 psoriasis launch. By Conor Hale The CorPath GRX Neurovascular System successfully completed 94% of its robotic-assisted procedures without the surgeon having to switch to a manual approach during the operation. Fierce podcasts Don't miss an episode | This week on "The Top Line," we discuss Sarepta's phase 2 Duchenne muscular dystrophy clinical trial that was green-lit earlier this week after a clinical hold in June. We also chat the opposing results on either side of the pond for Illumina quest for Grail. |
|
|---|
|
| Wednesday, September 28, 2022 | 2pm ET / 11am PT Explore the top line items every SMB marketer should focus on when commercializing new-to-market products, including shifts in the way that HCPs interact with pharma companies post-pandemic, and more. Register now. 
|
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Almac Pharma Services Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn AI eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent | | |
|
